SMTI
Sanara MedTech Inc.
Medical - Instruments & Supplies
Market Cap$170M
5Y Perf.+61.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SMTI vs XTNT
Revenue, margins, valuation, and 5-year total return — side by side.
XTNT
Xtant Medical Holdings, Inc.
Medical - Devices
Market Cap$80M
5Y Perf.-53.7%
SMTI vs XTNT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SMTI | XTNT |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $170M | $80M |
| Revenue (TTM) | $103M | $133M |
| Net Income (TTM) | $-38M | $2M |
| Gross Margin | 92.7% | 62.0% |
| Operating Margin | 4.9% | 4.8% |
| Forward P/E | 165.9x | — |
| Total Debt | $48M | $35M |
| Cash & Equiv. | $17M | $6M |
SMTI vs XTNT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SMTI
XTNT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Sanara MedTech Inc. (SMTI) | 100 | 161.0 | +61.0% |
| Xtant Medical Holdi… (XTNT) | 100 | 46.3 | -53.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SMTI vs XTNT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XTNT leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
SMTI
Sanara MedTech Inc.
The Long-Run Compounder
SMTI is the clearest fit if your priority is long-term compounding.
- 218.0% 10Y total return vs XTNT's -97.8%
Best for: long-term compounding
XTNT
Xtant Medical Holdings, Inc.
The Income Pick
XTNT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.69
- Rev growth 28.4%, EPS growth 107.7%, 3Y rev CAGR 28.5%
- Lower volatility, beta 0.69, Low D/E 81.8%, current ratio 2.35x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | XTNT | 28.4% revenue growth vs SMTI's 19.0% |
| Quality / Margins | XTNT | 1.3% margin vs SMTI's -36.4% |
| Stability / Safety | XTNT | Beta 0.69 vs SMTI's 1.42, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | XTNT | +10.0% vs SMTI's -40.1% |
| Efficiency (ROA) | XTNT | 1.8% ROA vs SMTI's -49.2%, ROIC -12.8% vs 11.8% |
SMTI vs XTNT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
FY 2024
SMTI vs XTNT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXTNTLAGGINGSMTI
SMTISanara MedTech Inc.
0leads
XTNTXtant Medical Holding…
3leads
6 Total Categories
CATEGORYLEADERvs SMTIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
XTNT3/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTNT6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
XTNT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — SMTI and XTNT each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
XTNT and SMTI operate at a comparable scale, with $133M and $103M in trailing revenue. XTNT is the more profitable business, keeping 1.3% of every revenue dollar as net income compared to SMTI's -36.4%. On growth, XTNT holds the edge at +19.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SMTISanara MedTech In… | XTNTXtant Medical Hol… |
|---|---|---|
| RevenueTrailing 12 months | $103M | $133M |
| EBITDAEarnings before interest/tax | $8M | $11M |
| Net IncomeAfter-tax profit | -$38M | $2M |
| Free Cash FlowCash after capex | $2M | $5M |
| Gross MarginGross profit ÷ Revenue | +92.7% | +62.0% |
| Operating MarginEBIT ÷ Revenue | +4.9% | +4.8% |
| Net MarginNet income ÷ Revenue | -36.4% | +1.3% |
| FCF MarginFCF ÷ Revenue | +2.1% | +3.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.6% | +19.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.8% | +123.7% |
Evenly matched — SMTI and XTNT each lead in 3 of 6 comparable metrics.
Valuation Metrics
XTNT leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | SMTISanara MedTech In… | XTNTXtant Medical Hol… |
|---|---|---|
| Market CapShares × price | $170M | $80M |
| Enterprise ValueMkt cap + debt − cash | $202M | $109M |
| Trailing P/EPrice ÷ TTM EPS | -4.38x | -4.75x |
| Forward P/EPrice ÷ next-FY EPS est. | 165.91x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 20.27x | — |
| Price / SalesMarket cap ÷ Revenue | 1.65x | 0.68x |
| Price / BookPrice ÷ Book value/share | 27.75x | 1.77x |
| Price / FCFMarket cap ÷ FCF | 78.85x | — |
XTNT leads this category, winning 3 of 3 comparable metrics.
Profitability & Efficiency
XTNT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
XTNT delivers a 3.8% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-179 for SMTI. XTNT carries lower financial leverage with a 0.82x debt-to-equity ratio, signaling a more conservative balance sheet compared to SMTI's 8.13x. On the Piotroski fundamental quality scale (0–9), SMTI scores 4/9 vs XTNT's 2/9, reflecting mixed financial health.
| Metric | SMTISanara MedTech In… | XTNTXtant Medical Hol… |
|---|---|---|
| ROE (TTM)Return on equity | -178.6% | +3.8% |
| ROA (TTM)Return on assets | -49.2% | +1.8% |
| ROICReturn on invested capital | +11.8% | -12.8% |
| ROCEReturn on capital employed | +15.6% | -17.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 8.13x | 0.82x |
| Net DebtTotal debt minus cash | $32M | $29M |
| Cash & Equiv.Liquid assets | $17M | $6M |
| Total DebtShort + long-term debt | $48M | $35M |
| Interest CoverageEBIT ÷ Interest expense | -9.97x | 1.55x |
XTNT leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — SMTI and XTNT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SMTI five years ago would be worth $7,170 today (with dividends reinvested), compared to $3,393 for XTNT. Over the past 12 months, XTNT leads with a +10.0% total return vs SMTI's -40.1%. The 3-year compound annual growth rate (CAGR) favors XTNT at -4.3% vs SMTI's -20.7% — a key indicator of consistent wealth creation.
| Metric | SMTISanara MedTech In… | XTNTXtant Medical Hol… |
|---|---|---|
| YTD ReturnYear-to-date | -17.4% | -24.0% |
| 1-Year ReturnPast 12 months | -40.1% | +10.0% |
| 3-Year ReturnCumulative with dividends | -50.1% | -12.3% |
| 5-Year ReturnCumulative with dividends | -28.3% | -66.1% |
| 10-Year ReturnCumulative with dividends | +218.0% | -97.8% |
| CAGR (3Y)Annualised 3-year return | -20.7% | -4.3% |
Evenly matched — SMTI and XTNT each lead in 3 of 6 comparable metrics.
Risk & Volatility
XTNT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
XTNT is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than SMTI's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTNT currently trades 60.0% from its 52-week high vs SMTI's 53.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SMTISanara MedTech In… | XTNTXtant Medical Hol… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.42x | 0.69x |
| 52-Week HighHighest price in past year | $35.95 | $0.95 |
| 52-Week LowLowest price in past year | $16.04 | $0.44 |
| % of 52W HighCurrent price vs 52-week peak | +53.1% | +60.0% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 57K | 142K |
XTNT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SMTISanara MedTech In… | XTNTXtant Medical Hol… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $32.00 | — |
| # AnalystsCovering analysts | 3 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XTNT leads in 3 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 2 categories are tied.
Best OverallXtant Medical Holdings, Inc. (XTNT)Leads 3 of 6 categories
Loading custom metrics...
SMTI vs XTNT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SMTI or XTNT a better buy right now?
For growth investors, Xtant Medical Holdings, Inc.
(XTNT) is the stronger pick with 28. 4% revenue growth year-over-year, versus 19. 0% for Sanara MedTech Inc. (SMTI). Analysts rate Sanara MedTech Inc. (SMTI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SMTI or XTNT?
Over the past 5 years, Sanara MedTech Inc.
(SMTI) delivered a total return of -28. 3%, compared to -66. 1% for Xtant Medical Holdings, Inc. (XTNT). Over 10 years, the gap is even starker: SMTI returned +218. 0% versus XTNT's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SMTI or XTNT?
By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.
(XTNT) is the lower-risk stock at 0. 69β versus Sanara MedTech Inc. 's 1. 42β — meaning SMTI is approximately 106% more volatile than XTNT relative to the S&P 500. On balance sheet safety, Xtant Medical Holdings, Inc. (XTNT) carries a lower debt/equity ratio of 82% versus 8% for Sanara MedTech Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SMTI or XTNT?
By revenue growth (latest reported year), Xtant Medical Holdings, Inc.
(XTNT) is pulling ahead at 28. 4% versus 19. 0% for Sanara MedTech Inc. (SMTI). Over a 3-year CAGR, SMTI leads at 31. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SMTI or XTNT?
Xtant Medical Holdings, Inc.
(XTNT) is the more profitable company, earning -14. 0% net margin versus -36. 4% for Sanara MedTech Inc. — meaning it keeps -14. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SMTI leads at 7. 1% versus -10. 3% for XTNT. At the gross margin level — before operating expenses — SMTI leads at 92. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SMTI or XTNT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SMTI or XTNT better for a retirement portfolio?
For long-horizon retirement investors, Xtant Medical Holdings, Inc.
(XTNT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69)). Both have compounded well over 10 years (XTNT: -97. 8%, SMTI: +218. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SMTI and XTNT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SMTI: 4.6% · XTNT: 19.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.